Goldstein D - Search Results

1

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Sosman JA, et al. Among authors: goldstein d. Cancer Invest. 1991;9(1):35-48. doi: 10.3109/07357909109032798. Cancer Invest. 1991. PMID: 2012995 Review.

2

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D, et al. Goldstein D, et al. Cancer Res. 1989 Dec 1;49(23):6832-9. Cancer Res. 1989. PMID: 2819723

3

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.

Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC. Goldstein D, et al. J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8. doi: 10.1093/jnci/81.14.1061. J Natl Cancer Inst. 1989. PMID: 2472488 Clinical Trial.

4

Absence of biological effects of orally administered interferon-beta ser.

Witt PL, Goldstein D, Storer BE, Grossberg SE, Flashner M, Colby CB, Borden EC. Witt PL, et al. Among authors: goldstein d. J Interferon Res. 1992 Dec;12(6):411-3. doi: 10.1089/jir.1992.12.411. J Interferon Res. 1992. PMID: 1289408

5

The role of interferon in cancer therapy: a current perspective.

Goldstein D, Laszlo J. Goldstein D, et al. CA Cancer J Clin. 1988 Sep-Oct;38(5):258-77. doi: 10.3322/canjclin.38.5.258. CA Cancer J Clin. 1988. PMID: 2458171 Free article. Review.

6

Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.

Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC. Goldstein D, et al. Cancer Res. 1989 May 15;49(10):2698-702. Cancer Res. 1989. PMID: 2469536

7

Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Gibson DF, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC. Gibson DF, et al. Among authors: goldstein d. Breast Cancer Res Treat. 1993;25(2):141-50. doi: 10.1007/BF00662139. Breast Cancer Res Treat. 1993. PMID: 8347846

8

Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.

Robinson SP, Goldstein D, Witt PL, Borden EC, Jordan VC. Robinson SP, et al. Among authors: goldstein d. Breast Cancer Res Treat. 1990 Feb;15(2):95-101. doi: 10.1007/BF01810781. Breast Cancer Res Treat. 1990. PMID: 2138919

9

A phase II study of crisnatol mesylate in patients with ovarian carcinoma.

Smalley RV, Goldstein D, Bulkowski D, Hannon C, Buchler D, Knudsen C, Tuttle RL. Smalley RV, et al. Among authors: goldstein d. Invest New Drugs. 1992 Jul;10(2):107-12. doi: 10.1007/BF00873127. Invest New Drugs. 1992. PMID: 1500264 Clinical Trial.

10

Effects of cytokines on the pituitary-adrenal axis in cancer patients.

Nolten WE, Goldstein D, Lindstrom M, McKenna MV, Carlson IH, Trump DL, Schiller J, Borden EC, Ehrlich EN. Nolten WE, et al. Among authors: goldstein d. J Interferon Res. 1993 Oct;13(5):349-57. doi: 10.1089/jir.1993.13.349. J Interferon Res. 1993. PMID: 8301155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,136 results

Search Page

Filters